ZNF384 and acute lymphoblastic leukemia: As shown in Fig. 4e–h, gilteritinib treatment led to a marked delay in leukemia progression compared to vehicle control (panel e: P < 0.005, panel g: P < 0.005) and also longer leukemia-free survival (panel f: P = 0.0027, panel h: P = 0.0026), despite variation in the in vivo growth rate of these two ZNF384-r ALL models.